Novavax (NVAX) Equity Ratio (2010 - 2026)

Novavax's Equity Ratio history runs 17 years deep, the most recent figure standing at 0.14 for Q1 2026.

• In Q1 2026, Equity Ratio fell 137.21% year-over-year to 0.14; the TTM figure through Mar 2026 stood at 0.14 (down 137.21% YoY), while the FY2025 annual figure was 0.11, up 72.84% from the prior year.
• Equity Ratio was 0.14 for Q1 2026 at Novavax, down from 0.11 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.03 in Q2 2025 to a low of 0.64 in Q1 2024.
• Historically, Equity Ratio has averaged 0.26 across 5 years, with a median of 0.25 in 2022.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio plunged 2619.33% in 2023, then surged 111.86% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.28 in 2022, then plunged by 42.08% to 0.4 in 2023, then dropped by 0.24% to 0.4 in 2024, then jumped by 72.84% to 0.11 in 2025, then slipped by 27.8% to 0.14 in 2026.
• The last three Equity Ratio figures came in at 0.14 (Q1 2026), 0.11 (Q4 2025), and 0.13 (Q3 2025), per Business Quant data.